NCT06713525

Brief Summary

The primary objective of the Copenhagen Pancreatic Cancer (COPAN) study is to describe the real-world population of patients with pancreatic cancer (PC). Larger sample of longitudinal real-world data provides a unique opportunity for comprehensive exploration of the diagnostic and treatment journey for individuals diagnosed with PC and allows to investigate treatment outcomes and associated prognostic factors. Furthermore, the study aims to identify determinants of treatment management and treatment outcomes, including patient-reported outcomes.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8,000

participants targeted

Target at P75+ for all trials

Timeline
129mo left

Started Dec 2025

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Dec 2025Dec 2036

First Submitted

Initial submission to the registry

November 24, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 3, 2024

Completed
12 months until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
10 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2035

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2036

Last Updated

December 3, 2024

Status Verified

November 1, 2024

Enrollment Period

10 years

First QC Date

November 24, 2024

Last Update Submit

November 27, 2024

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    3 years

Study Arms (1)

Patients with PC are referred to Comprehensive Pancreatic Cancer Center at Herlev Hospital

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with pancreatic cancer referred to Department of Oncology, Herlev Hospital, Denmark within the study period will be invited to participate.

You may qualify if:

  • Histologically confirmed pancreatic cancer

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Central Study Contacts

Inna Markovna Inna Markovna Chen, MD, Herlev & Gentofte Hospital, MD

CONTACT

+45 3868-2898Inna.Chen@regionh.dk

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

November 24, 2024

First Posted

December 3, 2024

Study Start

December 1, 2025

Primary Completion (Estimated)

December 1, 2035

Study Completion (Estimated)

December 1, 2036

Last Updated

December 3, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share